High levels of TNFalpha in patients with COVID-19 refractory to tocilizumab
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
European Journal of Cancer, sous presse, 2021, éditorial en libre accès
Résumé en anglais
Recently, Feldmann et al. in Lancet suggested investigating TNF alpha blocker therapies for patients with COVID-19 at high risk of developing a life-threatening form. The cytokine release syndrome and immuno-thrombosis induced by Sars-CoV2 mostly explains the severity of coronavirus disease 2019 (COVID-19). In a recent issue of Nature Medicine, Del Valle et al. reported the plasma levels of IL-6, IL-8, tumor necrosis factor (TNF)-
